We are delighted to invite you to two back-to-back meetings on HSPs and ataxias that will take place from March 12 to 14, 2025, in Heidelberg, Germany. We will start off with a Consensus Meeting on Demonstrating Meaningful Change in HSPs and Ataxias, followed by the Annual Meeting of the Tom Wahlig Foundation and the TreatHSP Network.
We look forward to welcoming numerous clinicians, scientists, patients, and other interested participants from around the world.
Please register via the following link: https://forms.gle/biwc5uzfUmP7EyuYA
Registration will be open until February 07, 2025.
Download the program here.
We have reserved contingents in the following two hotels for independent bookings under the keyword TWS/Tom Wahlig Foundation:
- IBIS Hauptbahnhof Heidelberg, Willy-Brandt-Platz 3, single room for 109,- € incl. breakfast, E-Mail: H1447@accor.com
- Intercity Hotel Heidelberg, Kurfürsten-Anlage 81, single room for € 115 incl. breakfast, e-mail: heidelberg@intercityhotel.com
Please also consider submitting an abstract (download template) and indicate your preferences for oral presentation as a Flash Talk or Poster Presentation. Abstract submission deadline is also February 07, 2025.
Consensus Meeting on Demonstrating Meaningful Change in HSPs and Ataxias (hosted by TreatHSP, AGI, ERDERA, ERN-RND, and the Tom Wahlig Foundation):
Breakthroughs in therapy development for HSPs and ataxias presents new challenges: How can we accurately assess the success of novel treatment approaches? In particular: are the improvements measured by our highly sensitive tools truly meaningful for patients - a question rightly emphasized by regulators? These methodological challenges in designing optimal studies are shared by many other rare diseases.
To address these pressing questions, TreatHSP and the Tom Wahlig Foundation have partnered with the Ataxia Global Initiative (AGI), the European Rare Disease Research Alliance (ERDERA), and the European Reference Network for Rare Neurological Diseases (ERN-RND) to organize multiple sessions under the theme "Demonstrating Meaningful Change".
Together, we aim to develop best practices and actionable strategies that will shape outcome validation studies and therapeutic trials in the years to come for the fields of ataxias and HSPs.
We invite you to contribute your expertise and insights to this vital discussion, alongside regulatory experts, representatives from the pharmaceutical industry, clinicians, scientists, and patient advocates.
Joint Annual Meeting of the TreatHSP Network and the Tom Wahlig Foundation (hosted by TreatHSP and the Tom Wahlig Foundation):
The second part of the meeting will then feature presentations on a range of translational topics related to hereditary spastic paraplegia (HSP), including genetics, biomarker research, the identification of new therapeutic approaches, and the introduction of the first clinical trials for disease-modifying therapies for HSP.
We look forward to your participation and a stimulating exchange of ideas that will drive progress in HSP and ataxia research and beyond.
You are warmly encouraged to register for both parts of the meeting if you wish, but you are equally welcome to register for just the parts that aligns most closely with your primary interests.
Please feel free to forward this invitation to colleagues and team members who may be interested in joining.